Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Abbott Xience Xpedition Drug Eluting Stent Gets Approval In Japan

RELATED NEWS
Trade ABT now with 

Healthcare company Abbott Laboratories (ABT: Quote) said Wednesday that it has received approval for its next-generation Xience Xpedition everolimus eluting coronary stent system in Japan. The approval boosts Abbott's efforts to globally expand its drug-eluting stent systems.

The company said that Japan's Ministry of Health, Labor and Welfare approved the Xience Xpedition stent for the treatment of coronary artery disease or CAD, the most common form of heart disease, in Japan. Heart disease is one of the leading causes of death in Japan, accounting for nearly one-third of all deaths in the country.

Abbott noted that the Xience Xpedition's enhanced deliverability, combined with the broadest size matrix in the Japanese market that includes a unique 3.25 mm diameter for more accurate vessel sizing, will help physicians in Japan address a wide range of patients with CAD.

Masahisa Yamane, director, Cardiovascular Division of Saitama Sekishinkai Hospital in Saitama, Japan said, "The deliverability with Xience Xpedition is impressive, helping physicians navigate with ease through complex blockages inside the heart vessels. This approval offers physicians an important new treatment option to address a growing health concern in Japan; we look forward to the positive impact of this product in Japanese patients with coronary heart disease."

Xience Xpedition is currently available in the U.S, Europe, the Middle East and parts of Asia.

In Japan, five Abbott-sponsored trials involving more than 3,000 patients implanted with either Xience V or Xience Prime have been conducted. Several other studies, including investigator-initiated trials, have been conducted since the original launch in Japan of Xience V in 2010.

In Wednesday's regular trading session, ABT is trading at $35.07, up $0.33 or 0.94 percent on a volume of 906,625 shares.

Register
To receive FREE breaking news email alerts for Abbott Laboratories and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Software giant Microsoft Corp. said Thursday after the markets closed that its first quarter profit fell 13% from last year, hurt mainly by integration and restructuring costs even as revenue surged 25% thanks to strong sales of its gadgets and cloud-based products. However, the company's quarterly earnings per share came in above analysts' expectations as did its quarterly revenue. After turning lower over the course of the previous session, stocks showed a substantial move back to the upside during trading on Thursday. The gains more than offset yesterday's loss, extending the recovery from the recent sell-off. Alaska Congressman Don Young, R-Ak., is once again making headlines with comments linking the state's high suicide rate to an increase in government assistance. Young told an audience at a senior center on Wednesday that the suicide problem didn't exist until there was "largesse" from the government.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.